longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

浙江博锐生物制药股份有限公司

N26016

----
Delay Pending: Sep 18, 16:08:00
Start trading
OverviewOverviewNewsNewsPostsPosts
LongbridgeAI
  • 08:38 ETWorld's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

    prnewswire·Apr 28 at 12:39 PM
    浙江博锐生物制药股份有限公司科兴生物制药股份有限公司